Literature DB >> 21522006

Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study.

Jean-Paul Viard1, Jean-Claude Souberbielle, Ole Kirk, Joanne Reekie, Brygida Knysz, Marcelo Losso, Jose Gatell, Court Pedersen, Johannes R Bogner, Jens D Lundgren, Amanda Mocroft.   

Abstract

BACKGROUND: We examined the association between vitamin D [25(OH)D] level and disease progression in HIV infection.
METHODS: Within the EuroSIDA study, 2000 persons were randomly selected for 25(OH)D measurement in stored plasma samples closest to study entry. 25(OH)D results were stratified into tertiles. Factors associated with 25(OH)D levels and associations of 25(OH) levels with subsequent risk of all-cause mortality, AIDS and non-AIDS events were analyzed.
RESULTS: Of 1985 persons with 25(OH)D levels available, 23.7% had 25(OH)D below 10, 65.3% between 10 and 30, and 11% above 30 ng/ml. At the time of 25(OH)D measurement, older persons, persons of black ethnic origin, living outside Southern Europe/Argentina, sampled during winter, and infected with HIV through nonhomosexual exposure were at higher odds of having low 25(OH)D levels, whereas persons receiving protease inhibitors were at lower odds. Compared to those in the lowest 25(OH)D tertile (<12 ng/ml), those in the middle (12-20) and higher (>20) tertiles had a significantly lower risk of clinical progression during subsequent follow-up. Adjusted incidence rate ratios for all-cause mortality were 0.68 (95% CI 0.47-0.99, P = 0.045) and 0.56 (95% CI 0.37-0.83, P = 0.0039), and for AIDS events were 0.58 (95% CI 0.39-0.87, P = 0.0086) and 0.61 (95% CI 0.40-0.93, P = 0.020), for the middle and higher tertiles, respectively. There was a similar, nonsignificant reduced incidence of non-AIDS events in the middle and higher tertiles.
CONCLUSION: 25(OH)D deficiency was frequent in HIV-infected persons (83% on combined antiretroviral therapy), and was independently associated with a higher risk of mortality and AIDS events. Causality relationships should be examined, because of potential public health consequences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21522006     DOI: 10.1097/QAD.0b013e328347f6f7

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  77 in total

1.  High prevalence of vitamin D deficiency in HIV-infected adults: what are the future research questions?

Authors:  Temitope Oyedele; Oluwatoyin M Adeyemi
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

2.  Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial.

Authors:  Rupak Shivakoti; Erin R Ewald; Nikhil Gupte; Wei-Teng Yang; Cecilia Kanyama; Sandra W Cardoso; Breno Santos; Khuanchai Supparatpinyo; Sharlaa Badal-Faesen; Javier R Lama; Umesh Lalloo; Fatima Zulu; Jyoti S Pawar; Cynthia Riviere; Nagalingeswaran Kumarasamy; James Hakim; Richard Pollard; Barbara Detrick; Ashwin Balagopal; David M Asmuth; Richard D Semba; Thomas B Campbell; Jonathan Golub; Amita Gupta
Journal:  Clin Nutr       Date:  2018-05-29       Impact factor: 7.324

3.  Vitamin D attenuates nucleoside reverse transcriptase inhibitor induced human skeletal muscle mitochondria DNA depletion.

Authors:  Grant R Campbell; Zachary T Pallack; Stephen A Spector
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

4.  High-dose vitamin D3 supplementation in children and young adults with HIV: a randomized, placebo-controlled trial.

Authors:  Virginia A Stallings; Joan I Schall; Mary L Hediger; Babette S Zemel; Florin Tuluc; Kelly A Dougherty; Julia L Samuel; Richard M Rutstein
Journal:  Pediatr Infect Dis J       Date:  2015-02       Impact factor: 2.129

Review 5.  Interventions to address chronic disease and HIV: strategies to promote exercise and nutrition among HIV-infected individuals.

Authors:  Diana Botros; Gabriel Somarriba; Daniela Neri; Tracie L Miller
Journal:  Curr HIV/AIDS Rep       Date:  2012-12       Impact factor: 5.071

6.  Habitual nutrient intake in HIV-infected youth and associations with HIV-related factors.

Authors:  Thomas R Ziegler; Grace A McComsey; Jennifer K Frediani; Erin C Millson; Vin Tangpricha; Allison Ross Eckard
Journal:  AIDS Res Hum Retroviruses       Date:  2014-07-16       Impact factor: 2.205

7.  Cross-sectional study of vitamin D levels, immunologic and virologic outcomes in HIV-infected adults.

Authors:  Allison Bearden; Cybele Abad; Ron Gangnon; James M Sosman; Neil Binkley; Nasia Safdar
Journal:  J Clin Endocrinol Metab       Date:  2013-03-01       Impact factor: 5.958

8.  Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.

Authors:  K M Klassen; M G Kimlin; C K Fairley; S Emery; P H Anderson; P R Ebeling
Journal:  Osteoporos Int       Date:  2015-12-11       Impact factor: 4.507

9.  Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol.

Authors:  Frantz Foissac; Jean-Marc Tréluyer; Jean-Claude Souberbielle; Hafeda Rostane; Saïk Urien; Jean-Paul Viard
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

Review 10.  Vitamin D deficiency and altered bone mineral metabolism in HIV-infected individuals.

Authors:  Allison Ross Eckard; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.